Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sweden’s Orexo Forms Partnership With Shanghai’s NovaMed To Enter Chinese Oncology Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Swedish pharmaceutical firm Orexo has signed an agreement with Shanghai-based NovaMed for the distribution of Orexo's cancer pain treatment Abstral (fast-dissolving fentanyl) in China

You may also be interested in...



Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline

SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)

Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline

SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)

NovaMed CEO Mark Lotter On Working With Pharma Distributors In China: An Interview With PharmAsia News

Shanghai-based NovaMed Pharmaceuticals was founded in August 2005 to provide distribution services for multinational pharmaceutical companies in China. NovaMed has signed China deals with several multinationals, including Baxter, Pfizer and Sanofi-Aventis. NovaMed Founder and CEO Mark Lotter recently participated in an email interview with PharmAsia News' Shanghai bureau about the changing contours of the pharmaceutical sector in China.

Related Content

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel